Walgreens Boots Alliance (NASDAQ:WBA – Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 1.400-1.800 for the period, compared to the consensus earnings per share estimate of 1.520. The company issued revenue guidance of -.
Walgreens Boots Alliance Stock Performance
Shares of NASDAQ:WBA opened at $9.22 on Friday. The firm has a fifty day simple moving average of $9.21 and a two-hundred day simple moving average of $9.92. The company has a quick ratio of 0.37, a current ratio of 0.68 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $7.96 billion, a P/E ratio of -0.92, a PEG ratio of 1.36 and a beta of 0.64. Walgreens Boots Alliance has a 52 week low of $8.08 and a 52 week high of $25.63.
Walgreens Boots Alliance (NASDAQ:WBA – Get Free Report) last announced its earnings results on Tuesday, October 15th. The pharmacy operator reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.03. The firm had revenue of $37.50 billion during the quarter, compared to analysts’ expectations of $35.75 billion. Walgreens Boots Alliance had a positive return on equity of 14.23% and a negative net margin of 5.85%. The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.67 EPS. On average, analysts expect that Walgreens Boots Alliance will post 1.53 earnings per share for the current fiscal year.
Walgreens Boots Alliance Dividend Announcement
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on WBA. Jefferies Financial Group reduced their price target on Walgreens Boots Alliance from $19.00 to $9.00 and set a “hold” rating on the stock in a report on Wednesday, October 23rd. Barclays increased their target price on Walgreens Boots Alliance from $7.00 to $8.00 and gave the stock an “underweight” rating in a research note on Wednesday, October 16th. Royal Bank of Canada lowered their target price on shares of Walgreens Boots Alliance from $13.00 to $9.00 and set a “sector perform” rating for the company in a research note on Wednesday, December 4th. Evercore ISI upped their price target on shares of Walgreens Boots Alliance from $7.50 to $10.00 and gave the stock an “in-line” rating in a report on Wednesday, October 16th. Finally, UBS Group lifted their price objective on shares of Walgreens Boots Alliance from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Thursday, October 17th. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $12.58.
Read Our Latest Research Report on WBA
Walgreens Boots Alliance Company Profile
Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.
Read More
- Five stocks we like better than Walgreens Boots Alliance
- How to Use the MarketBeat Stock Screener
- Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Is Domino’s Recent Dip a Recipe for Long-Term Gains?
- Trading Stocks: RSI and Why it’s Useful
- EV Sales Are Hitting Record Highs: 3 ETFs That Can Benefit
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.